Wolverine Trading
ABUS icon

Wolverine Trading’s Arbutus Biopharma ABUS Stock Holding History

Wolverine Trading’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$249K Buy
55,800
+11,800
+27% +$43.3K ﹤0.01% 4649
2025
Q2 		$138K Buy
44,000
+17,300
+65% +$57.4K ﹤0.01% 4074
2025
Q1 		$93.5K Sell
26,700
-2,400
-8% -$8K ﹤0.01% 4249
2024
Q4 		$93.1K Sell
29,100
-249,300
-90% -$917K ﹤0.01% 4821
2024
Q3 		$1.07M Buy
+278,400
New +$1.07M ﹤0.01% 2292
2023
Q1 		– Sell
-20,600
Closed -$48K – 4122
2022
Q4 		$48K Sell
20,600
-15,400
-43% -$36.8K ﹤0.01% 3586
2022
Q3 		$71K Buy
36,000
+10,300
+40% +$24.2K ﹤0.01% 4034
2022
Q2 		$69K Sell
25,700
-12,800
-33% -$32.8K ﹤0.01% 3961
2022
Q1 		$115K Sell
38,500
-6,700
-15% -$20.5K ﹤0.01% 4755
2021
Q4 		$175K Buy
+45,200
New +$176K ﹤0.01% 4792

Other funds holding ABUS

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Wolverine Trading's ABUS Position: Q4 2022 in Review

Wolverine Trading sold out of Arbutus Biopharma (ABUS) in Q4 2022, closing a stake of 11,032 shares — an estimated $26.4K sold.

Wolverine Trading first reported a position in ABUS in Q4 2021 and held it in 4 quarters. The position peaked at $59K in Q1 2022. 114 funds tracked by Wall St. Rank hold ABUS as of Q4 2022.

  • Wolverine Trading reported no remaining Arbutus Biopharma position as of Q4 2022 after selling out during the quarter.
  • Wolverine Trading sold 11,032 Arbutus Biopharma shares in Q4 2022, an estimated $26.4K.
  • Wolverine Trading first reported a position in Arbutus Biopharma in Q4 2021 and held it in 4 quarters.
  • Wolverine Trading's Arbutus Biopharma position peaked at $59K in Q1 2022.
  • 114 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q4 2022.

Based on Wolverine Trading's 13F filing for Q4 2022, filed 14 Feb 2023.